Latest Content

FDA approves gedatolisib for HR+/HER2- breast cancer. Learn about the VIKTORIA-1 trial, dosing, and nursing strategies for managing stomatitis.

FDA approves gedatolisib with fulvestrant for adults with HR+/HER2- metastatic breast cancer following endocrine therapy progression.

The FDA has granted traditional approval to selpercatinib for adult and pediatric patients with RET fusion-positive solid tumors post-progression.

Czarina Cecilio, BSN, RN, shares roundtable insights on toxicity management, injection techniques, and the critical role of nursing education.

FDA approves SC isatuximab-irfc with the CirCLIQ on-body injector, streamlining multiple myeloma care and reducing nursing burden.

The WHO 2026 report warns of a global cancer surge by 2050, highlighting critical inequities and the need for people-centered oncology nursing care.

Donna Berizzi discusses how LeanTaaS capacity management tools reduce nurse burnout by optimizing outpatient workflows and improving patient access.

FDA expanded pembrolizumab and enfortumab vedotin-ejfv for all surgery-eligible adults with muscle-invasive bladder cancer following positive trial data.

Experts explore the clinical promise, nursing implications, and access barriers of GLP-1s in cancer care.

FDA approves Ennumo (pegfilgrastim-pccg), a biosimilar to Neulasta, providing a new option for oncology nurses to manage chemotherapy-induced neutropenia.

Dr. Rodney Haring discusses the 2026 AACR Cancer Disparities Report and the critical role of oncology navigators in tribal and rural health equity.

ESMO GI 2026 data show patients under 50 receive more aggressive therapy yet face poorer survival, suggesting EOCRC is a distinct biological entity.

Study finds 86.5% of gastric/GEJ patients completed surgery after neoadjuvant chemo, significantly improving survival over those who did not.